Advanced diagnosis technologies for HER2 breast cancer markers
DOI:
https://doi.org/10.54097/hset.v14i.1591Keywords:
HER2, breast cancer, markers, FISH, IHC, CISH, NGS and Dual ISH.Abstract
Every year, the number of persons diagnosed with cancer depressive. As a result, cancer diagnosis is extremely crucial. Malignant tumor markers have become an important aspect of clinical tumor assessment, and different cancer cells have different markers. With the advancement of molecular biology technology, it is now possible to use it to diagnose, monitor, assess prognosis, forecast metastasis, and predict recurrence risk in malignant cancers. Breast cancer is the most frequent cancer among women, and the number of women diagnosed with it has been higher in many cancers. Histiocytic tumor markers in breast cancer include ER and PR, HER2,BRCA1 and BRCA2. Breast cancer can be categorized and treated using several markers, such as functional subtype HER-2 positive, and triple negative. As a result, precisely detecting the subtype of breast cancer is critical because it allows patients to receive the most effective treatment. HER2 is found in 30% of individuals diagnosed, with a poor prognosis and a significant recurrence rate. FISH, IHC, CISH, Dual ISH, and NGS are all common methods for detecting HER2 breast cancer. In this review, some of the most common HER2 breast cancer diagnostic procedures are summarized.
Downloads
References
A.G. Waks, E.P. Winer, Breast cancer treatment: a review [J]. Jama, 2019,321(3): 288-300.
E.S. McDonald, A.S. Clark, J. Tchou, et al., Clinical diagnosis and management of breast cancer [J]. Journal of Nuclear Medicine, 2016,57(Supplement 1): 9S-16S.
A. M Braden, R. V Stankowski, J. M Engel, et al., Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence [J]. Current pharmaceutical design, 2014,20(30): 4879-4898.
K.V. Nielsen, S. Müller, S. Møller, et al., Aberrations of ERBB2 and TOP2A genes in breast cancer[J]. Molecular oncology, 2010,4(2): 161-168.
M. Tanner, D. Gancberg, A. Di Leo, et al., Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples [J]. The American journal of pathology, 2000,157(5): 1467-1472.
D. de Melo Gagliato, D.L.F. Jardim, M.S.P. Marchesi, et al., Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer [J]. Oncotarget, 2016,7(39): 64431.
M.M. Moasser, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis [J]. Oncogene, 2007,26(45): 6469-6487.
S. Nagini, Breast cancer: current molecular therapeutic targets and new players [J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2017,17(2): 152-163.
A. Saez, F. Andreu, M. Segui, et al., HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases[J]. The breast, 2006,15(4): 519-527.
M. Wesoła, M. Jeleń, A comparison of IHC and FISH cytogenetic methods in the evaluation of HER2 status in breast cancer [J]. Adv Clin Exp Med, 2015,24(5): 899-903.
M. Liu, S.Q. Zhao, L. Yang, et al., A direct immunohistochemistry (IHC) method improves the intraoperative diagnosis of breast papillary lesions including breast cancer [J]. Discovery medicine, 2019,28(151): 29-37.
G.V.P. Okaly, D. Panwar, K.B. Lingappa, et al., FISH and HER2/neu equivocal immunohistochemistry in breast carcinoma [J]. Indian Journal of Cancer, 2019,56(2): 119.
[13] A. Akhdar, M. Bronsard, R. Lemieux, et al., HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH), Annales de pathologie, 2011, pp. 472-479.
L. Oberauner‐Wappis, M. Loibner, C. Viertler, et al., Protocol for HER 2 FISH determination on PAX gene‐fixed and paraffin‐embedded tissue in breast cancer [J]. International Journal of Experimental Pathology, 2016,97(2): 202-206.
L. Arnould, Y. Denoux, G. MacGrogan, et al., Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [J]. British journal of cancer, 2003,88(10): 1587-1591.
V. Bravatà, F.P. Cammarata, G.I. Forte, et al., “Omics” of HER2-positive breast cancer [J]. Omics: a journal of integrative biology, 2013,17(3): 119-129.
A. Halilovic, D.I. Verweij, A. Simons, et al., HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study[J]. Scientific Reports, 2019,9(1): 1-10.
A.C. Wolff, M.E.H. Hammond, K.H. Allison, et al., Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update [J]. Archives of pathology & laboratory medicine, 2018,142(11): 1364-1382.
H. Jiang, X. Bai, C. Zhang, et al., Evaluation of HER2 gene amplification in breast cancer using nuclei microarray in situ hybridization[J]. International Journal of Molecular Sciences, 2012,13(5): 5519-5527.
S. Ahn, J.W. Woo, K. Lee, et al., HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation [J]. Journal of pathology and translational medicine, 2020,54(1): 34-44.
J.S. Nix, S.A. Moore, What every neuropathologist needs to know: the muscle biopsy[J]. Journal of Neuropathology & Experimental Neurology, 2020,79(7): 719-733.
W.A. Mantilla, M.C. Sanabria-Salas, A.M. Baldion, et al., NGS in lung, breast, and unknown primary cancer in Colombia: a multidisciplinary consensus on challenges and opportunities[J]. JCO Global Oncology, 2021,71012-1023.
T.F. Beck, J.C. Mullikin, N.C.S.P.B.L.G.l.m.n. gov, Systematic evaluation of Sanger validation of next-generation sequencing variants [J]. Clinical chemistry, 2016,62(4): 647-654.
V. Probe, VENTANA HER2 Dual ISH DNA Probe Cocktail [J].
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
